Multiplex Assay Kit for Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) 
CD154; TRAP; HIGM1; IGM; IMD3; TBAM; T-BAM; TNFSF5; Gp39; TNF Superfamily Member 5; Hyper-IgM Syndrome; TNF-Related Activation Protein; T-Cell B-Cell Activating Molecule
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 405.00 US$ 420.00 US$ 443.00 US$ 475.00 US$ 506.00 US$ 552.00 US$ 622.00 US$ 778.00
- Quantity
Overview
Properties
- Product No.LMA119Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionCD & Adhesion moleculeApoptosisTumor immunityInfection immunityImmune molecule
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Cluster Of Differentiation 40 Ligand (CD40L) and the recovery rates were calculated by comparing the measured value to the expected amount of Cluster Of Differentiation 40 Ligand (CD40L) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 80-101 | 90 |
| EDTA plasma(n=5) | 79-92 | 83 |
| heparin plasma(n=5) | 93-101 | 96 |
| sodium citrate plasma(n=5) | 88-96 | 91 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cluster Of Differentiation 40 Ligand (CD40L) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-93% | 84-104% | 94-102% | 83-90% |
| EDTA plasma(n=5) | 90-101% | 91-101% | 96-105% | 78-95% |
| heparin plasma(n=5) | 89-98% | 79-102% | 87-101% | 94-102% |
| sodium citrate plasma(n=5) | 78-101% | 80-94% | 93-105% | 89-102% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:CD40L) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Cluster Of Differentiation 40 Ligand (CD40L) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Cluster Of Differentiation 40 Ligand (CD40L) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Cluster Of Differentiation 40 Ligand (CD40L) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Cluster Of Differentiation 40 Ligand (CD40L) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilationPubMed: 22899170
- The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in VivoPubmed:26760992
- Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis.pubmed:28114998
- Renal effects of metallothionein induction by zinc in vitro and in vivopubmed:28302075
- Effects of diisononyl phthalate on osteopenia in intact mice pubmed:28893586
- Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablationPubmed: 30857843
- Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers
- Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation
- Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular MarkersPubmed: 32812629
- Feasibility study of use of rabbit blood to evaluate platelet activation by medical devicesPubmed: 31838449
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyPubmed: 32085544
- Persistently higher serum sCD40L levels are associated with mortality in septic patients
- Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-¦ÊB and MAPK activation33981577
- Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy34820587